Monopar Therapeutics to Present Groundbreaking Research at AASLD

Author: Caleb Price Updated: 10-15-2025 08:18 AM

Monopar Therapeutics Announces Key Presentation at AASLD 2025

Today, Monopar Therapeutics Inc. (Nasdaq: MNPR), a dynamic clinical-stage biopharmaceutical company, proudly announced that its abstract focusing on the Phase 2 copper balance study has been selected for an engaging oral presentation at the prestigious American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025. This exciting meeting will be held in Washington, D.C. from November 7 to 11, 2025.

Presentation Highlights

Monopar's presentation is anticipated to shed light on important advancements in Wilson disease treatment, addressing a significant unmet medical need. This is a critical moment for the healthcare community and those affected by this condition. Here are some key details regarding the presentation:

Presentation Details

Title: Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline
Publication Number: 0073
Session: Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology
Date: Sunday, November 9, 9:00-9:15 am EST
Presenting Author: Aftab Ala, MBBS, M.D., FRCP, Ph.D.

Research Insights

At this conference, the presenting team will discuss the rapid improvement in copper balance observed in patients with Wilson disease being treated with the innovative drug Tiomolybdate Choline. This oral presentation marks a significant milestone in clinical research, emphasizing the potential of new therapeutic approaches in treating conditions related to aberrant copper metabolism.

About Monopar Therapeutics

Monopar Therapeutics is at the forefront of developing groundbreaking treatments that address unmet medical needs. In addition to the promising ALXN1840 for Wilson disease, the company is also pursuing various radiopharmaceutical programs. These include the early-stage MNPR-101-Zr for the imaging of advanced cancers, along with MNPR-101-Lu and MNPR-101-Ac225, which are designed for the treatment of advanced cancers.

The innovative solutions being developed by Monopar are representative of the company's commitment to improving patient outcomes and addressing the challenges faced by those with complex medical conditions.

Stay Updated

For those interested in following Monopar’s progress and the upcoming presentation materials, additional information will be made available on their official website. This initiative highlights the company’s dedication to transparency and community engagement in the healthcare sector.

Frequently Asked Questions

What is the significance of Monopar’s presentation at AASLD?

The presentation showcases groundbreaking research on a new treatment for Wilson disease, potentially improving patient outcomes.

When and where will the presentation take place?

The presentation is scheduled for November 9, 2025, during the AASLD conference in Washington, D.C.

Who is the presenting author for Monopar’s research?

Aftab Ala, MBBS, M.D., FRCP, Ph.D., will present the findings at the conference.

What is ALXN1840, and why is it important?

ALXN1840 is a treatment for Wilson disease, aiming to improve copper balance in patients, addressing a critical healthcare need.

How can I learn more about Monopar Therapeutics?

Visit the official website or follow Monopar on social media for updates on their innovative research and programs.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.